SCHEMBL6894345

SCHEMBL6894345

N#Cc1ccc(CN2CCN(S(=O)(=O)CCl)CC2=O)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 4/20 0.42
USP2 O75604 3/20 0.42
ALDH1A1 P00352 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
MEN1 O00255 1/20 0.42
MAPK1 P28482 1/20 0.42
KMT2A Q03164 1/20 0.42
HIF1A Q16665 1/20 0.42
FNTA P49354 1/20 0.41
FNTB P49356 1/20 0.41
PRMT5 O14744 3/20 0.40
WDR77 Q9BQA1 3/20 0.40
CYP2D6 P10635 4/20 0.39
TSHR P16473 2/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
CNR1 P21554 1/20 0.38
CYP1A2 P05177 1/20 0.38
DPP4 P27487 1/20 0.37
DPP8 Q6V1X1 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6896200 0.82 CYP3A4 (0.41) CYP3A4USP2ALDH1A1SMN1; SMN2MEN1
SCHEMBL6894382 0.81 USP2 (0.47) CYP3A4USP2ALDH1A1SMN1; SMN2MEN1
SCHEMBL6892965 0.78 USP2 (0.47) CYP3A4USP2ALDH1A1SMN1; SMN2MEN1
SCHEMBL16627277 0.77 PRMT5 (0.46) MEN1KMT2AFNTAFNTBPRMT5
SCHEMBL6895006 0.76 PKM (0.48) CYP3A4USP2ALDH1A1SMN1; SMN2MEN1
SCHEMBL6890055 0.76 F10 (0.54) CYP3A4USP2ALDH1A1SMN1; SMN2MEN1
SCHEMBL6890048 0.76 F10 (0.54) CYP3A4USP2ALDH1A1SMN1; SMN2MEN1
SCHEMBL6895122 0.76 USP2 (0.47) CYP3A4USP2ALDH1A1SMN1; SMN2MEN1
SCHEMBL6895154 0.76 F10 (0.49) KMT2AFNTAFNTBCNR1F10
SCHEMBL7436022 0.74 PRMT5 (0.55) CYP3A4USP2ALDH1A1SMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6680312-B2 FOR THERAPY OF CARDIAC INFARCTION, CEREBRAL THROMBOSIS; INHIBIT ACTIVATED COAGULATION FACTOR X (FXA) TO SHOW ANTI-COAGULANT ACTIVITY TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2004-01-20 US disclosed
US-20020193382-A1 Sulfonamide derivatives, their production and use TAKEDA PHARMACEUTICAL COMPANY, LIMITED (JP) 2002-12-19 US disclosed
US-6403595-B1 ANTICOAGULANTS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2002-06-11 US disclosed
EP-1054005-A1 SULFONAMIDE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND UTILIZATION THEREOF Takeda Chemical Industries, Ltd. (JP) 2000-11-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020193382-A1 Sulfonamide derivatives, their production and use F12, F11, F2 CYP3A4 168/4885USP2 3888/4885ALDH1A1 2304/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.